Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multiregional, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MST-168, in Participants With Advanced Solid Malignant Tumors

NCT07644650 is registered in ClinicalTrials.gov with Mabsoft Therapeutics (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07644650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07644650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multiregional, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MST-168, in Participants With Advanced Solid Malignant Tumors
Lead sponsor
Mabsoft Therapeutics (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
November 15, 2026
Completion date
June 30, 2030
Enrollment
420 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplams